FDA’s New Neuroscience Initiative Seeks to Foster Innovation, Accelerate Alzheimer’s Prevention
October 28, 2026Medical Devices, Policy, Food and Drug Administration (FDA), Healthcare Innovations
On October 22, 2026, the Food and Drug Administration (FDA) announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency-wide initiative focused on advancing medical product development for diseases and conditions affecting the brain and nervous system. The program seeks to advance the scientific tools and regulatory approaches in neuroscience product development to foster innovation on behalf of patients.
Search Results
Get the latest FDA and related regulatory developments critical to the life sciences industry delivered to your inbox.
